Literature DB >> 27394984

The dawn of a new era in onco-cardiology: The Kumamoto Classification.

Daisuke Sueta1, Noriaki Tabata1, Tomonori Akasaka1, Takayoshi Yamashita1, Tomokazu Ikemoto1, Seiji Hokimoto2.   

Abstract

The term "onco-cardiology" has been used in reference to cardiotoxicity in the treatment of malignant disease. In actual clinical situations, however, cardiovascular disease (CVD) associated with malignant disease and the concurrence of atherosclerotic disease with malignant disease are commonly observed, complicating the course of treatment. Patients with malignant disease associated with coronary artery disease often die from the cardiovascular disease, so it is essential to classify these disease states. Additionally, the prevalence of these classifications makes it easy to manage patients with malignant disease and coronary artery disease. We divided the broad field of onco-cardiology into 4 classifications based on clinical scenarios (CSs): CS1 represents the so-called paraneoplastic syndrome. CS2 represents cardiotoxicity during treatment of malignant diseases. CS3 represents the concurrence of atherosclerotic disease with malignant disease, and CS4 represents cardiovascular disease with benign tumors. This classification facilitates the management of patients with malignant disease and coronary artery disease by promoting not only the primary but also the secondary prevention of CVD.
Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Classification; Onco-cardiology

Mesh:

Substances:

Year:  2016        PMID: 27394984     DOI: 10.1016/j.ijcard.2016.06.330

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  5 in total

1.  Baseline Electrocardiographic and Echocardiographic Assessment May Help Predict Survival in Lung Cancer Patients-A Prospective Cardio-Oncology Study.

Authors:  Sabina Mędrek; Sebastian Szmit
Journal:  Cancers (Basel)       Date:  2022-04-15       Impact factor: 6.575

2.  A case of pulmonary thromboembolism due to coagulation factor V Leiden in Japan ~ usefulness of next generation sequencing~.

Authors:  Daisuke Sueta; Miwa Ito; Mitsuhiro Uchiba; Kenji Sakamoto; Eiichiro Yamamoto; Yasuhiro Izumiya; Sunao Kojima; Koichi Kaikita; Satoru Shinriki; Seiji Hokimoto; Hirotaka Matsui; Kenichi Tsujita
Journal:  Thromb J       Date:  2017-03-14

3.  Successful treatment of deep vein thrombosis caused by iliac vein compression syndrome with a single-dose direct oral anti-coagulant.

Authors:  Naoya Nakashima; Daisuke Sueta; Yusuke Kanemaru; Seiji Takashio; Eiichiro Yamamoto; Shinsuke Hanatani; Hisanori Kanazawa; Yasuhiro Izumiya; Sunao Kojima; Koichi Kaikita; Seiji Hokimoto; Kenichi Tsujita
Journal:  Thromb J       Date:  2017-02-01

Review 4.  Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis.

Authors:  Ming Yuan; Zhiwei Zhang; Gary Tse; Xiaojin Feng; Panagiotis Korantzopoulos; Konstantinos P Letsas; Bryan P Yan; William K K Wu; Huilai Zhang; Guangping Li; Tong Liu; Yunlong Xia
Journal:  Cardiol Res Pract       Date:  2019-04-14       Impact factor: 1.866

5.  Differential predictive factors for cardiovascular events in patients with or without cancer history.

Authors:  Daisuke Sueta; Noriaki Tabata; Satoshi Ikeda; Yuichi Saito; Kazuyuki Ozaki; Kenji Sakata; Takeshi Matsumura; Mutsuko Yamamoto-Ibusuki; Yoji Murakami; Takayuki Jodai; Satoshi Fukushima; Naoya Yoshida; Tomomi Kamba; Eiichi Araki; Hirotaka Iwase; Kazuhiko Fujii; Hironobu Ihn; Yoshio Kobayashi; Tohru Minamino; Masakazu Yamagishi; Koji Maemura; Hideo Baba; Kunihiko Matsui; Kenichi Tsujita
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.